

## Scibase - Strong start to the year

Redeye changes our short-term estimates slightly because of a better outcome than expected in the first quarter. The sales development was strong and a healthy gross margin was reported. The costs were in line apart from higher R&D costs. We reiterate our Base case at SEK 12 per share and unchanged fair value range of SEK 5 – 20 per share.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Scibase - Strong start to the year**